Myelofibrosis Epidemiology Forecast Research 2020-2034 - ResearchAndMarkets.com

The "Myelofibrosis - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

The report delivers an in-depth understanding of the myelofibrosis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Prominent clinical features in myelofibrosis include anemia, hepatosplenomegaly, and constitutional symptoms including fatigue, night sweats, low-grade fever, and progressive cachexia with loss of muscle mass, bone pain, splenic infarct, pruritus, non hepatosplenic EMH, thrombosis, and bleeding.

The myelofibrosis epidemiology division provides insights into the historical and current myelofibrosis patient pool and forecasted trends for seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted myelofibrosis epidemiology segmented by total prevalent cases, type-specific cases, myelofibrosis cases based on risk stratification, age-specific cases, and myelofibrosis cases based on molecular alterations in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2020 to 2034.

The total prevalent cases of myelofibrosis in the 7MM were nearly 56,700 in 2023 and is projected to increase during the study period (2020-2034). Among the EU4 and the UK, Germany accounted for the highest number of myelofibrosis diagnosed prevalent cases, followed by the Spain, whereas the UK accounted for the lowest number of cases in 2023. Based on risk, myelofibrosis cases are stratified as low risk, intermediate-1 risk, intermediate-2, and high risk. The high-risk accounted for the highest number of patients in 2023 in the US.

Myelofibrosis can be further categorized into primary myelofibrosis and secondary myelofibrosis. In 2023, primary myelofibrosis accounted for 75% of all cases in the US. In the US, based on age, myelofibrosis cases are stratified in the age group =49 years, 40-69 years, and =70 years. =70 years of age group accounted for the highest number of patients i.e. nearly 12,200 in 2023 in the US. In the US, the cases of JAK2 mutations account for approximately 60% in 2023.

KOL-Views

To keep up with current epidemiology trends, we take KOLs and SMEs' opinions working in the myelofibrosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate Myelofibrosis epidemiology trends.

Key Highlights

• Myelofibrosis consists of two entities: primary myelofibrosis and post-polycythemia vera (PPV) and post-essential thrombocythemia (PET) myelofibrosis, also known as secondary myelofibrosis.
• Mutations in the JAK2, MPL, CALR, and TET2 genes are associated with most cases of primary myelofibrosis. The JAK2 and MPL genes provide instructions for making proteins that promote the growth and division (proliferation) of blood cells.
• Approximately 90% of patients with myelofibrosis have a mutation of the JAK2, MPL, or CALR gene. The approximate frequencies of these mutations are JAK2 mutation: 60%, CALR mutation: 20-35%, and MPL mutation: 5-8%. About 10% of myelofibrosis patients do not have a JAK2, MPL, or CALR gene mutation. In these cases, the disease is referred to as "triple-negative" myelofibrosis and is associated with a worse prognosis (outcome).
• Prevalence rates of myelofibrosis have increased than previously reported, which may be explained by improved diagnostics, increased offerings for preventive checkups, and the classification change of prefibrotic myelofibrosis by the WHO in 2016.
• The total prevalent cases of myelofibrosis in the United States were nearly 19,300 in 2023. These cases are expected to rise during the forecast period (2024-2034).

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of myelofibrosis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts and disease progression has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Myelofibrosis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Age-wise cases of myelofibrosis

Myelofibrosis Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• Myelofibrosis Epidemiology Segmentation

Key Topics Covered:

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY OF MYELOFIBROSIS

4. EPIDEMIOLOGY METHODOLOGY

5. MYELOFIBROSIS EPIDEMIOLOGY OVERVIEW AT A GLANCE

5.1. PATIENT SHARE (%) OF MYELOFIBROSIS IN 2020

5.2. PATIENT SHARE (%) OF MYELOFIBROSIS IN 2034

6. DISEASE BACKGROUND AND OVERVIEW

6.1. INTRODUCTION

6.2. SUBTYPES

6.3. SIGNS AND SYMPTOMS

6.4. CAUSES

6.5. PATHOGENESIS

6.6. PROGNOSIS

6.7. RISK FACTOR

6.8. DIAGNOSIS

6.8.1. Blood test

6.8.2. Bone marrow tests

6.8.3. Molecular testing

6.8.4. Mutation-enhanced morphologic diagnosis

6.9. RISK-BASED SCORING IN MYELOFIBROSIS

7. EPIDEMIOLOGY AND PATIENT POPULATION

7.1. KEY FINDINGS

7.2. ASSUMPTIONS AND RATIONALE

7.3. TOTAL PREVALENT CASES OF MYELOFIBROSIS IN THE 7MM

7.4. THE UNITED STATES

7.4.1. Total Prevalent Cases of Myelofibrosis in the United States

7.4.2. Type-specific Cases of Myelofibrosis in the United States

7.4.3. Myelofibrosis Cases Based on Risk Stratification in the United States

7.4.4. Age-specific Cases of Myelofibrosis in the United States

7.4.5. Myelofibrosis Cases Based on Molecular Alterations in the United States

7.5. EU4 AND THE UK

7.5.1. Total Prevalent Cases of Myelofibrosis in EU4 and the UK

7.5.2. Type-specific Cases of Myelofibrosis in EU4 and the UK

7.5.3. Myelofibrosis Cases Based on Risk Stratification in EU4 and the UK

7.5.4. Age-specific Cases of Myelofibrosis in EU4 and the UK

7.5.5. Myelofibrosis Cases Based on Molecular Alterations in EU4 and the UK

7.6. JAPAN

7.6.1. Total Prevalent Cases of Myelofibrosis in Japan

7.6.2. Type-specific Cases of Myelofibrosis in Japan

7.6.3. Myelofibrosis Cases Based on Risk Stratification in Japan

7.6.4. Age-specific Cases of Myelofibrosis in Japan

7.6.5. Myelofibrosis Cases Based on Molecular Alterations in Japan

8. KOL VIEWS

9. APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/yl5jua

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212300969/en/